马拉韦罗：首次批准。

Maribavir: First Approval.

机构信息

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

出版信息

Drugs. 2022 Feb;82(3):335-340. doi: 10.1007/s40265-022-01677-4.

Abstract

Maribavir (LIVTENCITY), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (≥ 12 years of age and weighing ≥ 35 kg) patients. This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections.

摘要

马拉韦罗（利替卡因），一种巨细胞病毒（CMV）酶 pUL97 激酶抑制剂，由武田制药公司研发，用于治疗 CMV 感染。马拉韦罗最近在美国获得批准，用于治疗移植后 CMV 感染/疾病，这些患者对更昔洛韦、缬更昔洛韦、西多福韦或膦甲酸钠治疗（无论有无基因型耐药）无效，适用于成年和儿科（≥12 岁且体重≥35kg）患者。本文总结了马拉韦罗研发过程中的重要里程碑，最终该药获得 CMV 感染的首次批准。